5 results about "Clusterin" patented technology

The present invention relates to a method for predicting the outcome of liver transplantation for the treatment of hepatocellular carcinoma (HCC), or a method for arranging HCC patients to receive liver transplantation, comprising the following steps: determining the expression levels of indicator genes (including skin pontin, clusterin, calpain small subunit 1, F-box and WD repeat protein 7 and SproutyRTK signaling antagonist 2) selected from liver samples of patients suffering from HCC, and comparing the expression levels of the indicator genes with the expression levels of internal reference genes, and combining this with the variable total tumor volume through a linear support vector machine algorithm to predict a good prognosis for the liver transplant recipient.

The invention provides a Clusterin positive heart organoid and an application of the Clusterin positive heart organoid. The Clusterin positive heart organoid prepared by the method provided by the invention has more diverse cell compositions, and can better simulate the environment of the heart in a human body. The Clusterin positive heart organoid can be used for better improving the heart function.

Provided in the present invention are a clusterin-positive heart organoid and the use thereof. The clusterin-positive heart organoid prepared by means of the method of the present invention has more diversified cellular compositions, and can better simulate the environment of the heart in a human body. The clusterin-positive heart organoid can better improve cardiac functions.

The invention provides an application of a biomarker in predicting a gastric cancer immunotherapy effect and a related product. The biomarker is clustered protein. The gastric cancer treatment effect of the anti-PD-1 antibody can be predicted by detecting the expression level of clusterin or mRNA thereof in a gastric cancer tumor cell or tumor tissue sample. Furthermore, by inhibiting the expression level of clusterin, the gastric cancer treatment effect of the anti-PD-1 antibody can be improved. A new biomarker cluster protein is provided for predicting the gastric cancer treatment effect, and the cluster protein can be used as a novel target spot of the gastric cancer, so that a new direction is provided for screening drugs for treating the gastric cancer and treating the gastric cancer.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.